Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanSino BiologicsCASBF 65 3-Year Book Growth Rate is -10.10% as of Dec. 2025. GuruFocus rates CASBF with a GF Score™ of 65/100 and a GF Value™ of $9.14 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 910 Drug Manufacturers companies, CanSino Biologics ranks worse than 80.77% on this metric.
During the past 12 months, CanSino Biologics's average Book Value per Share Growth Rate was 4.60% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -10.10% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -9.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 10 years, the highest 3-Year average Book Value per Share Growth Rate of CanSino Biologics was 147.30% per year. The lowest was -18.80% per year. And the median was 60.60% per year.
CanSino Biologics (OTCPK:CASBF) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
CanSino Biologics 3-Year Book Growth Rate Related Terms
CASBF vs ZTS: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanSino Biologics 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where CanSino Biologics's 3-Year Book Growth Rate falls into.
CanSino Biologics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -10.10% mean?
CanSino Biologics (CASBF) has a 3-Year Book Growth Rate of -10.10% as of Dec. 2025. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for CanSino Biologics and its competitors. According to the industry distribution chart, CanSino Biologics ranks #735 out of 910 companies in the Drug Manufacturers industry, placing it in the top 80.8%.
Is CanSino Biologics' 3-Year Book Growth Rate too high?
CanSino Biologics' current 3-Year Book Growth Rate is -10.10%. Based on the distribution chart, CanSino Biologics ranks #735 out of 910 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, CanSino Biologics has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' 3-Year Book Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CanSino Biologics ranks #735 out of 910 companies for 3-Year Book Growth Rate. This places CanSino Biologics in the lower half of its industry. The industry median 3-Year Book Growth Rate is 4.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.60, based on 910 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for CanSino Biologics and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanSino Biologics's current 3-Year Book Growth Rate is -10.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (CASBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.14, compared to a current price of $4.60 — trading 49.7% below its estimated fair value. The current 3-Year Book Growth Rate is -10.10%. CanSino Biologics' overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For CanSino Biologics (CASBF), the current 3-Year Book Growth Rate is -10.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CanSino Biologics (CASBF) Overvalued in 2026?
Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued.
The current stock price of $4.60 is trading 49.7% below its estimated GF Value™ of $9.14.
GuruFocus considers CanSino Biologics to be Significantly Undervalued.
Key valuation signals for CASBF:
3-Year Book Growth Rate: -10.10%
GF Value™: $9.14 vs. price of $4.60 (49.7% below fair value)
No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
65GF Score
Get the complete analysis for CASBF
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASBF has been successfully added to your 
